Your browser doesn't support javascript.
loading
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Ahn, Peter H; Machtay, Mitchell; Anne, Pramila R; Cognetti, David; Keane, William M; Wuthrick, Evan; Dicker, Adam P; Axelrod, Rita S.
Afiliação
  • Ahn PH; Departments of Radiation Oncology.
  • Machtay M; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA.
  • Anne PR; Departments of Radiation Oncology.
  • Cognetti D; Department of Radiation Oncology, Case Western Reserve University, Cleveland.
  • Keane WM; Departments of Radiation Oncology.
  • Wuthrick E; Otolaryngology.
  • Dicker AP; Otolaryngology.
  • Axelrod RS; Departments of Radiation Oncology.
Am J Clin Oncol ; 41(5): 441-446, 2018 05.
Article em En | MEDLINE | ID: mdl-27391356
ABSTRACT

OBJECTIVES:

Bevacizumab (avastin) and erlotinib (tarceva) had shown early clinical activity against head and neck cancer (HNC). We initiated a phase I trial of induction cisplatin, docetaxel, 5-fluorouracil and erlotinib (TPF-E) followed by cisplatin, bevacizumab and erlotinib (PA-E) with radiotherapy (XRT) for advanced HNC. The goal was to determine maximum tolerated erlotinib dose.

METHODS:

Eligible patients had stage IVA or higher HNC with good performance status, hematologic, and renal reserve. Two cycles of induction TPF-E were administered. XRT was administered with concurrent weekly cisplatin and bevacizumab every 2 weeks. Initial erlotinib dose was 50 mg daily from start of induction chemotherapy until radiotherapy completion. Erlotinib dose escalations to 100 and 150 mg were planned.

RESULTS:

Thirteen patients with previously untreated locoregional disease (11 patients) or oligometastatic (2 patients) HNC were enrolled. Totally, 11 of 13 patients completed XRT as planned. Four of 8 patients in cohort 1 (erlotinib 50 mg), 3 of 4 patients in cohort 2 (100 mg), and 0 of 1 patients in cohort 3 (150 mg) completed the regimen. Two patients had significant gastrointestinal complications (bleeding and perforation), and 1 had dose-limiting diarrhea. Maximum tolerated dose was reached at 50 mg erlotinib. At median 23.4 months follow-up, 5 patients (38%) have no evidence of disease, and 2 (15%) have stable but measurable disease.

CONCLUSIONS:

Erlotinib in combination with induction TPF followed by erlotinib, cisplatin, and bevacizumab with XRT is active but toxic. Gastrointestinal toxicities partly caused high rates of study withdrawal. All doses studied in this protocol caused unexpected toxicities and we do not recommend advancement to phase II.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Quimiorradioterapia / Neoplasias de Cabeça e Pescoço Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Clin Oncol Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Quimiorradioterapia / Neoplasias de Cabeça e Pescoço Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Clin Oncol Ano de publicação: 2018 Tipo de documento: Article